
    
      PROTOCOL OUTLINE: This is a randomized, double-blind study. Patients are stratified by
      participating institution and Ludwig histologic stage.

      All patients are treated with ursodiol (ursodeoxycholic acid, UDCA) for 6 months. If entry
      criteria continue to be met, patients are randomly assigned to UDCA/methotrexate or
      UDCA/placebo.

      Combination therapy continues for at least 5 years.
    
  